• 1. Ir(iii)-Catalyzed [4 + 2] cyclization of azobenzene and diazotized Meldrum's acid for the synthesis of cinnolin-3(2H)-one
  Gongutri Borah,Pitambar Patel Org. Biomol. Chem. 2019 17 2554
• 2. Ring contraction of 1,2,4-triazin-3-ones to imidazolin-2-ones and 1,2,3-triazoles
  Charles W. Rees,Alan A. Sale J. Chem. Soc. Perkin Trans. 1 1973 545
• 3. Ring contraction of 1,2,4-triazin-3-ones to imidazolin-2-ones and 1,2,3-triazoles
  Charles W. Rees,Alan A. Sale J. Chem. Soc. Perkin Trans. 1 1973 545
• 4. An isothiourea-catalyzed asymmetric formal [4 + 2] cycloaddition of in situ generated azoalkenes with C1 ammonium enolates
  Zi-Jing Zhang,Jin Song Org. Chem. Front. 2018 5 2578
• 5. Synthesis, structure–activity relationships and stereochemical investigations of new tricyclic pyridazinone derivatives as potential STAT3 inhibitors
  Daniela Masciocchi,Arianna Gelain,Federica Porta,Fiorella Meneghetti,Alessandro Pedretti,Giuseppe Celentano,Daniela Barlocco,Laura Legnani,Lucio Toma,Byoung-Mog Kwon,Akira Asai,Stefania Villa Med. Chem. Commun. 2013 4 1181

Recent Advances in the Study of 2,3-Dihydrocinnolin-3-one (CAS: 31777-46-5) in Chemical Biology and Pharmaceutical Research

The compound 2,3-dihydrocinnolin-3-one (CAS: 31777-46-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This heterocyclic scaffold, characterized by a fused benzene and pyridazine ring, has been explored for its role in modulating various biological targets, including kinases, proteases, and other enzymes involved in disease pathways. Recent studies have highlighted its versatility as a pharmacophore, enabling the development of novel inhibitors and probes for both academic and industrial applications.

One of the most notable advancements in the study of 2,3-dihydrocinnolin-3-one is its application in the design of kinase inhibitors. Kinases play a critical role in cellular signaling and are often implicated in cancer and inflammatory diseases. Researchers have synthesized a series of derivatives based on the 2,3-dihydrocinnolin-3-one core, demonstrating potent inhibitory activity against specific kinases such as JAK2 and CDK2. These findings, published in recent journals like the Journal of Medicinal Chemistry, underscore the compound's potential as a lead structure for the development of targeted therapies.

In addition to its kinase inhibitory properties, 2,3-dihydrocinnolin-3-one has also been investigated for its role in modulating protein-protein interactions (PPIs). PPIs are notoriously challenging targets for small-molecule intervention, but the rigid and planar structure of this compound has shown promise in disrupting key interactions involved in diseases such as Alzheimer's and Parkinson's. A 2023 study in ACS Chemical Biology reported the successful use of 2,3-dihydrocinnolin-3-one derivatives as selective disruptors of tau protein aggregation, a hallmark of neurodegenerative disorders.

The synthetic accessibility of 2,3-dihydrocinnolin-3-one further enhances its appeal as a scaffold for drug discovery. Recent methodologies, including transition-metal-catalyzed cyclizations and multicomponent reactions, have streamlined the production of diverse derivatives with improved pharmacokinetic properties. For instance, a team at the University of Cambridge developed a one-pot synthesis route that significantly reduces the number of steps required to generate functionalized 2,3-dihydrocinnolin-3-one analogs, as detailed in a 2022 Organic Letters publication.

Despite these promising developments, challenges remain in optimizing the selectivity and bioavailability of 2,3-dihydrocinnolin-3-one-based compounds. Computational modeling and structure-activity relationship (SAR) studies are being employed to address these issues, with recent efforts focusing on the incorporation of solubilizing groups and the exploration of novel substitution patterns. A preprint on bioRxiv highlights the use of machine learning algorithms to predict the binding affinities of new derivatives, potentially accelerating the discovery of clinically viable candidates.

In conclusion, 2,3-dihydrocinnolin-3-one (CAS: 31777-46-5) represents a versatile and promising scaffold in chemical biology and pharmaceutical research. Its applications span from kinase inhibition to the modulation of protein-protein interactions, supported by advances in synthetic chemistry and computational design. As research continues to uncover its full potential, this compound is poised to play a pivotal role in the development of next-generation therapeutics for a range of diseases.

• 5468-36-0(2,3,5,6,7,8-hexahydrocinnolin-3-one)
• 108749-03-7(2,3,5,6,7,8-hexahydrocinnolin-3-one hydrobromide)
• 679405-98-2(3(2H)-Pyridazinone, 6-methyl-5-propyl- (9CI))
• 61404-50-0(5-ethyl-2,3-dihydropyridazin-3-one)
• 122001-78-9(2H,3H,5H,6H,7H-cyclopenta[c]pyridazin-3-one)
• 7143-82-0(3-methyl-1H-pyridazin-6-one;hydrate)
• 39716-45-5(2H,3H,5H,6H,7H,8H,9H-cyclohepta[c]pyridazin-3-one)
• 825634-15-9(3(2H)-Pyridazinone, 5-ethenyl-)
• 94248-99-4(3-methyl-1H-pyridazin-6-one;hydrobromide)
• 126751-21-1(5,6-dihydro-7-methyl-3(2H)-Cinnolinone)